Quoin Pharmaceuticals/$QNRX
Quoin Pharmaceuticals ADR rises after reporting statistically significant positive interim Phase 2/3 results for QRX003 in Netherton Syndrome.
22 hours agoLightyear AI
1D1W1MYTD1Y5YMAX
About Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
- Ticker
- $QNRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 5
- Headquarters
- Ashburn, United States
- Website
- quoinpharma.com
QNRX Metrics
BasicAdvanced
$12M
-
-$8.52
1.66
-
Price and volume
Market cap
$12M
Beta
1.66
52-week high
$41.80
52-week low
$3.25
Average daily volume
1.1M
Financial strength
Current ratio
1.76
Quick ratio
1.633
Long term debt to equity
36.203
Total debt to equity
51.46
Profitability
EBITDA (TTM)
-19.045
Management effectiveness
Return on assets (TTM)
-114.60%
Return on equity (TTM)
-575.73%
Valuation
Price to book
3.13
Price to tangible book (TTM)
3.41
Price to free cash flow (TTM)
-0.878
Free cash flow yield (TTM)
-113.93%
Free cash flow per share (TTM)
-6.973
Growth
Earnings per share change (TTM)
-73.98%
3-year earnings per share growth (CAGR)
-76.28%
QNRX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.